{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:17:34Z","timestamp":1788520654196,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"DOI":"10.1186\/s13044-025-00223-0","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T18:03:18Z","timestamp":1739124198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["BRAFV600E mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Di","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-4413","authenticated-orcid":false,"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6095-4728","authenticated-orcid":false,"given":"Yansong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"8","key":"223_CR1","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9940","key":"223_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328.","journal-title":"Lancet"},{"issue":"7","key":"223_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330.","journal-title":"N Engl J Med"},{"issue":"7","key":"223_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674\u201384.","journal-title":"Ann Oncol"},{"issue":"1","key":"223_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s44178-022-00015-8","volume":"1","author":"M Ge","year":"2022","unstructured":"Ge M, Gao M, Cheng R, Chen X, Guan H, Lin Y, et al. CACA guidelines for holistic integrative management of thyroid cancer. Holistic Integrative Oncology. 2022;1(1):17.","journal-title":"Holistic Integrative Oncology"},{"issue":"3","key":"223_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.21147\/j.issn.1000-9604.2022.03.01","volume":"34","author":"Health Commission Of The People\u2019s Republic Of China N","year":"2022","unstructured":"Health Commission Of The People\u2019s Republic Of China N. National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):131\u201350.","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"223_CR7","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555\u201367.","journal-title":"Lancet Glob Health"},{"issue":"15","key":"223_CR8","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1158\/1078-0432.CCR-22-3613","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, et al. Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2023;29(15):2791\u20139.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"223_CR9","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-22-3406","volume":"29","author":"Y Chi","year":"2023","unstructured":"Chi Y, Zheng X, Zhang Y, Shi F, Cheng Y, Guo Z, et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase II trial. Clin Cancer Res. 2023;29(20):4047\u201356.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"223_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","volume":"8","author":"Y Lin","year":"2022","unstructured":"Lin Y, Qin S, Li Z, Yang H, Fu W, Li S, et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial. JAMA Oncol. 2022;8(2):242\u201350.","journal-title":"JAMA Oncol"},{"issue":"5","key":"223_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.21147\/j.issn.1000-9604.2022.05.02","volume":"34","author":"H Wang","year":"2022","unstructured":"Wang H, Wang J, Wang X, Zhu Y, Sun Y, Zhang X, et al. Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(5):447\u201350.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"223_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jncc.2024.06.005","volume":"4","author":"H Zeng","year":"2024","unstructured":"Zeng H, Zheng R, Sun K, Zhou M, Wang S, Li L, et al. Cancer survival statistics in China 2019\u20132021: a multicenter, population-based study. J Natl Cancer Cent. 2024;4(3):203\u201313.","journal-title":"J Natl Cancer Cent"},{"key":"223_CR13","unstructured":"Cancer Stat Facts: Thyroid Cancer: National Cancer Institute. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/thyro.html. [cited 2024 5 October]."},{"issue":"8","key":"223_CR14","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1089\/thy.2020.0779","volume":"31","author":"MH Taylor","year":"2021","unstructured":"Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid. 2021;31(8):1226\u201334.","journal-title":"Thyroid"},{"key":"223_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejca.2017.01.013","volume":"75","author":"M Tahara","year":"2017","unstructured":"Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, et al. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017;75:213\u201321.","journal-title":"Eur J Cancer"},{"key":"223_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","volume":"106","author":"M Tahara","year":"2019","unstructured":"Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019;106:61\u20138.","journal-title":"Eur J Cancer"},{"issue":"23","key":"223_CR17","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","volume":"35","author":"MS Brose","year":"2017","unstructured":"Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 2017;35(23):2692\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"223_CR18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cncr.34181","volume":"128","author":"N Kiyota","year":"2022","unstructured":"Kiyota N, Tahara M, Robinson B, Schlumberger M, Sherman SI, Leboulleux S, et al. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer. 2022;128(12):2281\u20137.","journal-title":"Cancer"},{"issue":"3","key":"223_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1507\/endocrj.EJ17-0365","volume":"65","author":"K Sugino","year":"2018","unstructured":"Sugino K, Nagahama M, Kitagawa W, Ohkuwa K, Uruno T, Matsuzu K, et al. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr J. 2018;65(3):299\u2013306.","journal-title":"Endocr J"},{"issue":"9","key":"223_CR20","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/hed.25784","volume":"41","author":"C Suzuki","year":"2019","unstructured":"Suzuki C, Kiyota N, Imamura Y, Goto H, Suto H, Chayahara N, et al. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head Neck. 2019;41(9):3023\u201332.","journal-title":"Head Neck"},{"issue":"3","key":"223_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"223_CR22","doi-asserted-by":"publisher","first-page":"e3027","DOI":"10.1210\/clinem\/dgab196","volume":"106","author":"YS Lin","year":"2021","unstructured":"Lin YS, Zhang X, Wang C, Liu YQ, Guan WM, Liang J. Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer. J Clin Endocrinol Metab. 2021;106(8):e3027\u201336.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"223_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1089\/thy.2020.0235","volume":"31","author":"YS Lin","year":"2021","unstructured":"Lin YS, Yang H, Ding Y, Cheng YZ, Shi F, Tan J, et al. Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial. Thyroid. 2021;31(4):607\u201315.","journal-title":"Thyroid"},{"issue":"5","key":"223_CR24","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.eprac.2024.02.005","volume":"30","author":"D Sun","year":"2024","unstructured":"Sun D, Zhang X, Sun Y, Mu Z, Wang H, Zhang Y, et al. Early structural, biochemical, and metabolic responses to anlotinib in patients with progressive radioactive iodine refractory differentiated thyroid cancer. Endocr Pract. 2024;30(5):456\u201364.","journal-title":"Endocr Pract"},{"issue":"2","key":"223_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"223_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2967\/jnumed.116.180240","volume":"58","author":"X Yang","year":"2017","unstructured":"Yang X, Li J, Li X, Liang Z, Gao W, Liang J, et al. TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med. 2017;58(2):258\u201365.","journal-title":"J Nucl Med"},{"issue":"5","key":"223_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1210\/clinem\/dgad697","volume":"109","author":"Z Mu","year":"2024","unstructured":"Mu Z, Zhang X, Sun D, Sun Y, Shi C, Ju G, et al. Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer. J Clin Endocrinol Metab. 2024;109(5):1231\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"223_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385\u201395.","journal-title":"Stat Med"},{"issue":"20","key":"223_CR29","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1158\/1078-0432.CCR-21-0761","volume":"27","author":"X Zheng","year":"2021","unstructured":"Zheng X, Xu Z, Ji Q, Ge M, Shi F, Qin J, et al. A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2021;27(20):5502\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"223_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/SLA.0b013e318148563d","volume":"246","author":"E Kebebew","year":"2007","unstructured":"Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466\u201370 discussion 70-1.","journal-title":"Ann Surg"},{"issue":"14","key":"223_CR31","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"M Xing","year":"2013","unstructured":"Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493\u2013501.","journal-title":"JAMA"},{"issue":"12","key":"223_CR32","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"223_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245\u201362.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"223_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1507\/endocrj.K08E-208","volume":"56","author":"Y Ito","year":"2009","unstructured":"Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56(1):89\u201397.","journal-title":"Endocr J"},{"issue":"5","key":"223_CR35","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1245\/s10434-024-14935-4","volume":"31","author":"HF Lai","year":"2024","unstructured":"Lai HF, Hang JF, Kuo PC, Kuo CS, Yao SF, Chen JY, Lee CH. BRAF V600E mutation lacks association with poorer clinical prognosis in papillary thyroid carcinoma. Ann Surg Oncol. 2024;31(5):3495\u2013501.","journal-title":"Ann Surg Oncol"},{"key":"223_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/1477-7819-11-291","volume":"11","author":"SY Choi","year":"2013","unstructured":"Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol. 2013;11:291.","journal-title":"World J Surg Oncol"},{"issue":"10","key":"223_CR37","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1210\/jc.2019-00431","volume":"104","author":"D Perera","year":"2019","unstructured":"Perera D, Ghossein R, Camacho N, Senbabaoglu Y, Seshan V, Li J, et al. Genomic and transcriptomic characterization of papillary microcarcinomas with lateral neck lymph node metastases. J Clin Endocrinol Metab. 2019;104(10):4889\u201399.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"223_CR38","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1001\/jamaoto.2013.4501","volume":"139","author":"C Gouveia","year":"2013","unstructured":"Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg. 2013;139(11):1164\u201370.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"2","key":"223_CR39","first-page":"e230297","volume":"13","author":"S Ahmadi","year":"2024","unstructured":"Ahmadi S, Landa I. The prognostic power of gene mutations in thyroid cancer. Endocr Connect. 2024;13(2):e230297.","journal-title":"Endocr Connect"},{"issue":"2","key":"223_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","volume":"20","author":"I Landa","year":"2024","unstructured":"Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol. 2024;20(2):93\u2013110.","journal-title":"Nat Rev Endocrinol"},{"issue":"25","key":"223_CR41","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718\u201326.","journal-title":"J Clin Oncol"},{"issue":"16","key":"223_CR42","doi-asserted-by":"publisher","first-page":"E1600","DOI":"10.1073\/pnas.1404357111","volume":"111","author":"DG McFadden","year":"2014","unstructured":"McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A. 2014;111(16):E1600-9.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"223_CR43","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052\u201366.","journal-title":"J Clin Invest"},{"issue":"1","key":"223_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","volume":"13","author":"G Riesco-Eizaguirre","year":"2006","unstructured":"Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I- targeting to the membrane. Endocr Relat Cancer. 2006;13(1):257\u201369.","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"223_CR45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/RLU.0000000000000498","volume":"39","author":"K Yang","year":"2014","unstructured":"Yang K, Wang H, Liang Z, Liang J, Li F, Lin Y. BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med. 2014;39(8):675\u20139.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"223_CR46","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1210\/jc.2006-2707","volume":"92","author":"C Durante","year":"2007","unstructured":"Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92(7):2840\u20133.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"223_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21147\/j.issn.1000-9604.2024.01.03","volume":"36","author":"Z Mu","year":"2024","unstructured":"Mu Z, Zhang X, Liang D, Fang J, Chen G, Guo W, et al. Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer. Chin J Cancer Res. 2024;36(1):25\u201335.","journal-title":"Chin J Cancer Res"},{"issue":"35","key":"223_CR48","doi-asserted-by":"publisher","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","volume":"9","author":"P Yu","year":"2023","unstructured":"Yu P, Qu N, Zhu R, Hu J, Han P, Wu J, et al. TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Sci Adv. 2023;9(35):eadg7125.","journal-title":"Sci Adv"},{"issue":"16_suppl","key":"223_CR49","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.1200\/JCO.2024.42.16_suppl.6098","volume":"42","author":"FP Worden","year":"2024","unstructured":"Worden FP, Wirth LJ, Reynolds N, Cooper C, Rajkovic-Hooley O, Milligan G, et al. Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and\/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy. J Clin Oncol. 2024;42(16_suppl):6098.","journal-title":"J Clin Oncol"},{"issue":"24","key":"223_CR50","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1158\/1078-0432.CCR-18-3439","volume":"25","author":"MS Brose","year":"2019","unstructured":"Brose MS, Schlumbeger M, Jeffers M, Kappeler C, Meinhardt G, Pena CEA. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: subanalysis of the sorafenib phase III DECISION trial. Clin Cancer Res. 2019;25(24):7370\u201380.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"223_CR51","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1210\/jc.2005-2836","volume":"91","author":"YS Jo","year":"2006","unstructured":"Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91(9):3667\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"223_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1210\/er.2007-0007","volume":"28","author":"M Xing","year":"2007","unstructured":"Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742\u201362.","journal-title":"Endocr Rev"},{"issue":"10","key":"223_CR53","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1002\/ijc.22110","volume":"119","author":"S Hu","year":"2006","unstructured":"Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006;119(10):2322\u20139.","journal-title":"Int J Cancer"},{"issue":"4","key":"223_CR54","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nm846","volume":"9","author":"JH Qi","year":"2003","unstructured":"Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9(4):407\u201315.","journal-title":"Nat Med"},{"issue":"10","key":"223_CR55","first-page":"1184","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, et al. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, Phase 2, open-label multicenter trial. Thyroid. 2022;32(10):1184\u201392.","journal-title":"Thyroid"},{"issue":"27","key":"223_CR56","doi-asserted-by":"publisher","first-page":"15846","DOI":"10.1073\/pnas.2004707117","volume":"117","author":"J Tan","year":"2020","unstructured":"Tan J, Liu R, Zhu G, Umbricht CB, Xing M. TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proc Natl Acad Sci U S A. 2020;117(27):15846\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"223_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.009","volume":"161","author":"CM Thielmann","year":"2022","unstructured":"Thielmann CM, Matull J, Zaremba A, Murali R, Chorti E, Lodde G, et al. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. Eur J Cancer. 2022;161:99\u2013107.","journal-title":"Eur J Cancer"},{"issue":"4","key":"223_CR58","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1634\/theoncologist.2019-0633","volume":"25","author":"L Cheng","year":"2020","unstructured":"Cheng L, Fu H, Jin Y, Sa R, Chen L. Clinicopathological features predict outcomes in patients with radioiodine-refractory differentiated thyroid cancer treated with sorafenib: a real-world study. Oncologist. 2020;25(4):e668\u201378.","journal-title":"Oncologist"},{"issue":"5","key":"223_CR59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1530\/EJE-12-0405","volume":"167","author":"TC Schneider","year":"2012","unstructured":"Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012;167(5):643\u201350.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"223_CR60","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1530\/EJE-09-0702","volume":"161","author":"H Hoftijzer","year":"2009","unstructured":"Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923\u201331.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"223_CR61","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1210\/jc.2015-3989","volume":"101","author":"B Robinson","year":"2016","unstructured":"Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, et al. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab. 2016;101(11):4103\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"223_CR62","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1530\/EJE-13-0825","volume":"170","author":"MH Massicotte","year":"2014","unstructured":"Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014;170(4):575\u201382.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"223_CR63","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1210\/jc.2009-1923","volume":"95","author":"ME Cabanillas","year":"2010","unstructured":"Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95(6):2588\u201395.","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"223_CR64","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.3390\/cancers13174429","volume":"13","author":"S Kato","year":"2021","unstructured":"Kato S, Demura S, Shinmura K, Yokogawa N, Shimizu T, Tsuchiya H. Current management of bone metastases from differentiated thyroid cancer. Cancers (Basel). 2021;13(17):4429.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"223_CR65","doi-asserted-by":"publisher","first-page":"e6727","DOI":"10.1002\/cam4.6727","volume":"13","author":"J Shen","year":"2024","unstructured":"Shen J, Yan M, Chen L, Ou D, Yao J, Feng N, et al. Prognosis and influencing factors of follicular thyroid cancer. Cancer Med. 2024;13(1):e6727.","journal-title":"Cancer Med"},{"issue":"12","key":"223_CR66","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","volume":"83","author":"SA Hundahl","year":"1998","unstructured":"Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638\u201348.","journal-title":"Cancer."},{"issue":"10","key":"223_CR67","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1210\/clinem\/dgae181","volume":"109","author":"V Marotta","year":"2024","unstructured":"Marotta V, Rocco D, Crocco A, Deiana MG, Martinelli R, Di Gennaro F, et al. Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in real life. J Clin Endocrinol Metab. 2024;109(10):2541\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"223_CR68","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","volume":"25","author":"AG Gianoukakis","year":"2018","unstructured":"Gianoukakis AG, Dutcus CE, Batty N, Guo M, Baig M. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer. 2018;25(6):699\u2013704.","journal-title":"Endocr Relat Cancer"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-025-00223-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T18:03:25Z","timestamp":1739124205000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-025-00223-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["223"],"URL":"https:\/\/doi.org\/10.1186\/s13044-025-00223-0","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the trials were approved by the Ethics Committee of Peking Union Medical College Hospital. All patients provided written informed consent before participating in the trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}